Lombard Odier Asset Management (Switzerland) Sa Apellis Pharmaceuticals, Inc. Transaction History

Lombard Odier Asset Management (Switzerland) Sa

$1.14 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $4.62 Million - $6.64 Million	-99,173 Reduced 58.22%	71,180 $4.7 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $1.76 Million - $2.49 Million	40,776 Added 31.47%	170,353 $8.81 Million
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $2.93 Million - $4.57 Million	-65,549 Reduced 33.59%	129,577 $8.85 Million
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $916,203 - $1.55 Million	-26,125 Reduced 11.81%	195,126 $8.82 Million
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $7.18 Million - $11 Million	-202,425 Reduced 47.78%	221,251 $11.2 Million
Q4 2021 Feb 14, 2022	BUY	$30.74 - $49.16 $6.67 Million - $10.7 Million	216,930 Added 104.93%	423,676 $20 Million
Q3 2021 Nov 12, 2021	SELL	$31.4 - $69.84 $5.91 Million - $13.1 Million	-188,287 Reduced 47.66%	206,746 $6.81 Million
Q2 2021 Aug 13, 2021	BUY	$40.9 - $64.9 $639,594 - $1.01 Million	15,638 Added 4.12%	395,033 $25 Million
Q1 2021 May 17, 2021	BUY	$40.8 - $57.39 $15.5 Million - $21.8 Million	379,395 New	379,395 $16.3 Million

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

Wellington Management Group LLP Boston, MA

15.6M
Shares

$516 Million
0.08% of portfolio
Eco R1 Capital, LLC San Francisco, CA

11.9M
Shares

$394 Million
14.88% of portfolio
Avoro Capital Advisors LLC New York, NY

11.1M
Shares

$368 Million
4.82% of portfolio
Vanguard Group Inc Valley Forge, PA

9.82M
Shares

$325 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.8M
Shares

$192 Million
0.01% of portfolio

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Switzerland) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Lombard Odier Asset Management (Switzerland) Sa with notifications on news.

Account